drugset
drugset / Trial / NCT05966493

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493 ↗

Phase 2 Recruiting 84 enrolled Glaukos Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.

Timeline

Start
2023-08-17
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CODA-001 Unknown — Topical

Indications

corneal disorder